Stockscreener 앱 받기
569.90
1.07%
6.04
시간 외 거래:
569.90
전일 마감가:
$563.86
열려 있는:
$569.02
하루 거래량:
853.20K
Relative Volume:
0.84
시가총액:
$59.37B
수익:
$14.21B
순이익/손실:
$4.46B
주가수익비율:
14.36
EPS:
39.6877
순현금흐름:
$3.56B
1주 성능:
-5.02%
1개월 성능:
+2.40%
6개월 성능:
-1.18%
1년 성능:
-43.70%
1일 변동 폭
$563.51
$574.72
1주일 범위
$560.97
$618.01
52주 변동 폭
$476.49
$1,024.36
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
414.86 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.95 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
804.90 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
335.80 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks? - MSN
Libtayo’s CSCC Label Expansion Broadens Practitioner Base - insights.citeline.com
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients - Benzinga
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’ - Stocktwits
Regeneron, needing a turnaround, gains new use for cancer drug - BioPharma Dive
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo - The Globe and Mail
New FDA approval for Libtayo - The Pharma Letter
Will Regeneron Pharmaceuticals Inc. continue its uptrend2025 Sector Review & Community Shared Stock Ideas - newser.com
Regeneron Pharmaceuticals Inc. stock daily chart insights2025 Year in Review & Real-Time Volume Analysis Alerts - newser.com
8,976 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Bar Harbor Wealth Management - MarketBeat
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery - Yahoo
Bispecific Antibodies MarketGlobal Forecast 2025-2032, Profiles of Key PlayersF. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab - GlobeNewswire
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by QRG Capital Management Inc. - MarketBeat
Regeneron Pharmaceuticals (REGN) Stock: Dips Despite FDA’s Breakthrough Approval for Libtayo in High-Risk CSCC - parameter.io
US FDA expands use of Regeneron’s Libtayo as add-on treatment for skin cancer - 104.1 WIKY
Libtayo approved in the U.S. for adjuvant treatment of cutaneous squamous cell carcinoma - MarketScreener
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer - Reuters
Regeneron (REGN) Gains FDA Approval for Cancer Therapy Libtayo - GuruFocus
FDA Approves Regeneron's Libtayo for High-Risk Skin Cancer Treat - GuruFocus
FDA Approves Regeneron's (REGN) Libtayo for High-Risk Skin Cance - GuruFocus
Regeneron Pharmaceuticals Announces FDA Approval of Libtayo® as Adjuvant Treatment for High-Risk Cutaneous Squamous Cell Carcinoma - Quiver Quantitative
Regeneron stock rises after FDA approves Libtayo for high-risk skin cancer - Investing.com
68% Risk Reduction: Regeneron's Libtayo Approved as First Adjuvant Immunotherapy for CSCC - Stock Titan
Regeneron Pharma stock price target raised by RBC to $704 on Dupixent growth By Investing.com - Investing.com Nigeria
Regeneron Pharma stock price target raised by RBC to $704 on Dupixent growth - Investing.com
RBC Raises Price Target on Regeneron Pharmaceuticals to $704 From $695, Keeps Sector Perform Rating - MarketScreener
Dohj LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KLP Kapitalforvaltning AS Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Valeo Financial Advisors LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ameliora Wealth Management Ltd. - MarketBeat
Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Slow Capital Inc. - MarketBeat
Regeneron Pharmaceuticals to Acquire 23andMe for $256M - MSN
Galderma Punches Above Its Weight Against Dermatology Goliaths - insights.citeline.com
Regeneron Pharmaceuticals (REGN): Valuation in Focus Following Breakthrough Pipeline Results and Expanded Drug Approvals - simplywall.st
Strategies to average down on Regeneron Pharmaceuticals Inc.2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Regeneron (REGN) Projects $83 Million R&D Charge in Q3 2025 - GuruFocus
Regeneron expects $83 million IPR&D charge in third quarter 2025 results - Investing.com
Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Earnings Miss & Advanced Technical Signal Analysis - newser.com
Can trapped investors hope for a rebound in Regeneron Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - newser.com
Is Regeneron Pharmaceuticals Inc. stock resilient to inflationQuarterly Market Review & Verified Technical Trade Signals - newser.com
111 Capital Makes New $517,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
J. Safra Sarasin Holding AG Sells 438 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Janney Montgomery Scott LLC Has $6.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Published on: 2025-10-06 01:04:19 - newser.com
Marietta Wealth Management LLC Has $6.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why pension funds invest in Regeneron Pharmaceuticals Inc. (RGO) stock2025 Support & Resistance & Daily Risk Controlled Trade Plans - newser.com
Applying Elliott Wave Theory to Regeneron Pharmaceuticals Inc.Weekly Stock Recap & Accurate Buy Signal Alerts - newser.com
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockRisk Management & Expert Approved Momentum Trade Ideas - newser.com
Why Regeneron (REGN) Is Up 6.4% After FDA Expansion and Positive Late-Stage Trial Results - simplywall.st
Mirae Asset Global Investments Co. Ltd. Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
4.36%
자본화:
|
볼륨(24시간):